[Compound nylestriol tablet to prevent bone loss in osteoporotic rats].
OBJECTIVE
To investigate the effects of compound nylestriol tablet (CNT), containing nylestriol and levonorgestrel with a ratio of 1:0.3) and its components on the osteoporotic rat model induced by retinoic acid (RA) and ovariectomy (OVX).


METHODS
We randomly divided 144 female SD rats (aged 7-month-old) into 12 groups (12 in each). In addition, 120 female SD rats aged 4-month were randomly divided into 10 groups (10 in each). Three dosage levels of CNT (0.039, 0.117 and 0.39 mg/kg body weight, daily), nylestriol (NYL, 0.30, 0.09 and 0.03 mg/kg body weight, daily) and levonorgestrel (LEV, 0.09, 0.027 and 0.009 mg/kg body weight, daily) were designed to prevent the bone loss of the osteoporotic rat model induced by RA and OVX respectively. Serum total calcium (Ca), phosphate (Pi), ALP, triglyceride (TG), total cholesterol (TC), HDL-C, total body BMD, isolated left femoral BMD and femoral Ca, and Pi after ashing were determined.


RESULTS
Osteoporotic models could be induced by RA (70 mg/kg body weightdaily given intragastrically for 14 days) or by ovariectomy; CNT and its components had the preventive effects on bone loss in both models; The preventive effect of CNT was dose-dependent and stronger than its components; Many observed markers showed us the levels of high and moderate CNT given to be the strongest, corresponding to an optimal choice of the moderate dose CNT about one tablet per week in adult women.


CONCLUSIONS
CNT therapy can prevent the bone loss of RA-induced and OVX-induced osteoporotic rats, and its therapeutic and preventive effect is better than its components used alone.
Liu
Shi-Ping
SP
Insititute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, China.
Liao
Er-Yuan
EY
Wu
Xian-Ping
XP
Luo
Xiang-Hang
XH
Li
Huan-De
HD
Chen
Ze-Neng
ZN
Dai
Ru-Chun
RC
Sun
Rui-Yuan
RY
Liu
Xi-Jiu
XJ
D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D002118:Calcium / Q000097:blood; D004338:Drug Combinations; D005260:Female; D016912:Levonorgestrel / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D010052:Ovariectomy; D010758:Phosphorus / Q000097:blood; D011800:Quinestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013607:Tablets; D014212:Tretinoin
D004338:Drug Combinations; D013607:Tablets; D010758:Phosphorus; D014212:Tretinoin; D016912:Levonorgestrel; C010722:nylestriol; D000469:Alkaline Phosphatase; D011800:Quinestrol; D002118:Calcium